Turn Therapeutics Inc. TTRX
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -- | 323.37% | -- | 136.82% | -- |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -- | 340.38% | -- | 115.45% | -- |
| Operating Income | -- | -340.38% | -- | -115.45% | -- |
| Income Before Tax | -- | -129.74% | -- | -108.00% | -- |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -- | -129.74% | -- | -108.00% | -- |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -- | -129.74% | -- | -108.00% | -- |
| EBIT | -- | -340.38% | -- | -115.45% | -- |
| EBITDA | -- | -349.71% | -- | -117.79% | -- |
| EPS Basic | -- | -118.08% | -- | -99.71% | -- |
| Normalized Basic EPS | -- | -118.46% | -- | -100.00% | -- |
| EPS Diluted | -- | -118.08% | -- | -99.71% | -- |
| Normalized Diluted EPS | -- | -118.46% | -- | -100.00% | -- |
| Average Basic Shares Outstanding | -- | 5.92% | -- | 3.04% | -- |
| Average Diluted Shares Outstanding | -- | 5.92% | -- | 3.04% | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |